Skip to content

Laser for Oral Mucositis in Pediatric Onco-hematology

LAMPO: Multicenter Randomized Double-blind Controlled Trial to Evaluate the Efficacy of Laser Therapy for Treatment of Oral Mucositis Induced by Chemotherapy in Children

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02762019
Acronym
LAMPO
Enrollment
101
Registered
2016-05-04
Start date
2013-09-30
Completion date
2015-10-31
Last updated
2016-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stomatitis

Keywords

Stomatitis, Laser, Children, Chemotherapy, Treatment

Brief summary

Children with cancer undergoing intensive chemotherapy (CT) regimens experience many side effects among which oral mucositis (OM) is one of the most debilitating. Modifications of CT's schedule and prolonged hospitalization may be necessary in presence of OM, causing poor general conditions and debilitation. Moreover, the use of narcotic analgesics and total parenteral nutrition may be required, triggering not only a physical deficit but also an economic burden. Despite the frequency and impact of OM among children with cancer, there is no consensus on standard therapy for this condition. Previous studies demonstrated that high power laser therapy can help the maintenance of nutritional status in patients with OM and can remarkably reduce costs/resources needed. Laser therapy has evidence of efficacy in reducing symptoms and in preventing the onset of OM in adult cancer patients but only one randomized controlled trial, with a limited number of children enrolled, supports its use in children for treatment of OM induced by chemotherapy. This multicenter double-blind randomized controlled trial evaluates the efficacy of laser for treatment of oral mucositis secondary to chemotherapy in children aged 3-17 years. The study involves 8 italian hospitals.

Interventions

DEVICELaser therapy

Treatment with K-Laser Cube3 during 4 consecutive days, with the following protocol: 660-970 nm wavelength, 3,2W mean power (6.4W pulsating at 50%), 3'51'' duration, 1-20000 Hz frequency, and 1 cm2 spot size. Laser application was performed all over the oral cavity.

DEVICESham therapy

Only the laser pointer movement, without laser activation, during 4 consecutive days, all over the oral cavity.

Sponsors

IRCCS Burlo Garofolo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
3 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Children aged 3-18 years * Oral mucositis of grade 3 or 4 at enrollment (CTC - WHO scale) * Antiblastic chemotherapy in the in the previous three weeks * Willingness to undergo treatment for 4 consecutive days and to return for evaluation 7 and 11 days after enrollment.

Exclusion criteria

* Previous treatment with laser therapy for stomatitis * Presence of dysplastic oral lesions * Reduction of mouth opening (\<1 cm) * Localized head and/or neck radiation treatment in the previous 4 weeks * Use of keratinocyte growth factor (KGF) * Previous enrollment in the study

Design outcomes

Primary

MeasureTime frameDescription
Reduction of the grade of oral mucositis7 days after enrollmentReduction of stomatitis' grade (from grade 3 or 4 to a lower grade). The grade of stomatitis is defined using the World Health Organization (WHO) evaluation scale

Secondary

MeasureTime frameDescription
Reduction of the grade of oral mucositis3 days after enrollmentReduction of stomatitis' grade (from grade 3 or 4 to a lower grade). The grade of stomatitis is defined using the WHO evaluation scale
Reduction of pain, age 4-7 years3 days after enrollmentReduction of self-reported pain recorded with the Faces Pain Scale-Revised (FPS-R)
Reduction of pain, age 8-18 years3 days after enrollmentReduction of self-reported pain recorded with a numeric rating scale
Reduction of need for analgesicsat day 7
Adverse eventsat day 11

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026